

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 003300-903	APPLICATION NO. 10/048,016
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT PER ANTONSSON <i>et al.</i>	
	FILING DATE January 28, 2002	GROUP 1648

MAY 14 2003

10

U.S. PATENT DOCUMENTS

RECEIVED

MAY 16 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AS	Harald Zur Hausen, "Viruses in Human Cancers, Science 22 November 1991; Vol. 254: Pages 1167 to 1173.
AS	Douglas R. Lowry et al., "Papillomaviruses and Cervical Cancer: Pathogenesis and Vaccine Development", Journal of the National Cancer Institute Monographs No. 23, 1998, Pages 27 to 30.
	Wendy I. White et al., "In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16", Journal of Virology, Feb. 1998, Vol. 72, No. 2, Pages 959 to 964.
	Heather L. Greenstone et al., "Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model", Proc. National Academy of Sciences, USA, February 1998, Vol. 95, Pages 1800 to 1805.
	Shiwen Peng et al., "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class I Pathway", Virology, 1998, 240: Pages 147 to 157.
	Martin Müller et al., "Chimeric Papillomavirus-like Particles", Virology, 1997, 234: Pages 93 to 111.
	Wendy I. White et al., "Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1", Journal of Virology, June 1999, Vol. 73, No. 6, Pages 4882 to 4889.
	Zhaohui Wang et al., "A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera", Journal of General Virology, 1997, 78: Pages 2209 to 2215.

Examiner Signature		Date Considered	7/17/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO <i>JUL 07 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. PATENT & TRADEMARK OFFICE</i>	ATTORNEY'S DKT NO. 003300-903	APPLICATION NO. 10/048,016
APPLICANT Per ANTONSSON <i>et al.</i>	FILING DATE January 28, 2002	
GROUP 1648		

U.S. PATENT DOCUMENTS

RECEIVED
JUL 11 2003
TECH CENTER 160012000

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AS	Marjory SPRAYCAR <i>et al.</i> , Eds., Definition of "Derivative", Stedman's Medical Dictionary, 26th Edition, 1995, pgs. 461-462, Williams & Wilkins, Baltimore, Maryland, USA
AS	Neil D. CHRISTENSEN <i>et al.</i> , "Assembled Baculovirus-Expressed Human Papillomavirus Type 11 L1 Capsid Protein virus-Like Particles are Recognized by Neutralizing Monoclonal Antibodies and Induce High Titres of Neutralizing Antibodies", Journal of General Virology, 1994, pgs. 2271-2276, Vol. 75, Society for General Microbiology, London, ENGLAND
AS	John D. NIELAND <i>et al.</i> , "Chimeric Papillomavirus Virus-Like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response", Journal of Cellular Biochemistry, 1999, pgs. 145-152, Vol. 73, Wiley-Liss, New York, New York, USA

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

05/03)